Skip to main content
Premium Trial:

Request an Annual Quote

Revenues Are Up, But Xenometrix Still Posts Loss for Previous Quarter


BOULDER, Colo.--Xenometrix, a biotechnology company here that uses its proprietary gene profiling technology to help the pharmaceutical industry optimize drug leads, has released financial results for the quarter ended September 30 that a show a slight gain in revenue over the same period a year ago, but a loss in net income and net per share. The losses are in part the result of a loss of grant money, greater R&D expenditures, new interest expenses, and an extraordinary gain recorded in the comparable period in 1996.

Xenometrix recorded sales and service revenue of $199,000 in the last quarter, compared to $166,000 a year ago. The company ascribed the gain to increased sales of its gene profile assays. Gross profit also grew from $2,000 for the quarter in 1996 to $54,000 this year. R&D expenditures grew from $250,000 to $373,000, reflecting, among other things, Xenometrix's focus on building a bioinformatics database. Except for R&D, the company's operating expenses fell compared to 1996 spending.

Xenometrix reported a net loss of $894,000, or 30 cents per share for the quarter. The company has obtained a $1.5 million line of credit to help it meet liquidity needs, which should be sufficient to meet expenses through the end of the year, officials said.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.